APONTIS PHARMA
's headquarters is located in Monheim, North Rhine-Westphalia. APONTIS PHARMA has been a Merger Pending of Zentiva AG since Mar 2025. APONTIS PHARMA has 1 followers on Owler.APONTIS PHARMA
's headquarters is located in Monheim, North Rhine-Westphalia. APONTIS PHARMA has been a Merger Pending of Zentiva AG since Mar 2025. APONTIS PHARMA has 1 followers on Owler.
Annual Revenue
<$1M
Employees
<10
News
Aug 20, 2025
centralcharts
Press Release: APONTIS PHARMA : EQS-News: APONTIS PHARMA: Changes in the management board
Jun 19, 2025
Marketscreener
APONTIS PHARMA: Apontis Pharma : Information pursuant to Section 125 AktG and Table 3 Blocks A to F Implementing Regulation EU 2018/1212 (2 2025 apontis pharma apontis pharma information according to section 125 aktg and table 3 blocks a to f implementing regulation eu 2018 1212)
Jun 13, 2025
centralcharts
Press Release: APONTIS PHARMA : EQS-Adhoc: APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
May 15, 2025
centralcharts
Press Release: APONTIS PHARMA : EQS-News: APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025
Mar 31, 2025
centralcharts
Press Release: APONTIS PHARMA : EQS-News: APONTIS PHARMA with significant sales and earnings increase in 2024 financial year - squeeze-out and merger planned
Mar 05, 2025
centralcharts
Press Release: APONTIS PHARMA : EQS-Adhoc: APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger squeeze-out of the minority shareholders of APONTIS PHARMA AG
Mar 05, 2025
Marketscreener
APONTIS PHARMA: APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger squeeze-out of the minority shareholders of APONTIS PHARMA AG - merger agreement planned
Dec 09, 2024
FinanzNachrichten
APONTIS PHARMA: Zentiva completes voluntary public purchase offer for APONTIS PHARMA AG
Aug 09, 2024
Marketscreener
APONTIS PHARMA: Apontis Pharma AG Reports Earnings Results for the Half Year Ended June 30, 2024
Jun 27, 2024
MarketScreener
APONTIS PHARMA: APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company